TRIM26 deficiency drives gastric cancer lymph node metastasis via TGF-β signaling activation and modulates gemcitabine response - PubMed
4 hours ago
- #chemoresistance
- #TRIM26
- #gastric-cancer
- TRIM26 deficiency in gastric cancer (GC) drives lymph node metastasis (LNM) via TGF-β signaling activation.
- TRIM26 loss promotes pro-metastatic interactions between epithelial cells, endothelial cells, and macrophages through SELE-CD44 and SPP1-CD44/integrin axes.
- Downregulation of TRIM26 correlates with poor survival and metabolic reprogramming of taurine and pantothenate/CoA pathways.
- TRIM26-low tumors show reduced sensitivity to gemcitabine, supported by higher estimated IC50 values and stable drug binding in simulations.
- TRIM26 overexpression inhibits tumor growth and invasiveness, especially in the presence of gemcitabine.
- TRIM26 serves as a prognostic and predictive biomarker, offering potential for precision therapy in GC.